Senl 1904A / SenlangBio - LARVOL DELTA

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Hebei Senlang Biotechnology Inc., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2020 ➔ Jan 2022; Trial primary completion date: Sep 2019 ➔ Sep 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19